vadadustat + calcium acetate

Vadadustat + calcium acetate is a combination of two drugs used primarily in patients with chronic kidney disease (CKD) undergoing dialysis who frequently experience anemia and hyperphosphatemia. **Vadadustat** is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes endogenous erythropoietin production by stabilizing HIF transcription factors, thereby increasing red blood cell production and correcting anemia associated with CKD. **Calcium acetate** is a phosphate binder that acts by binding dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate, which is then excreted in the feces, thus reducing hyperphosphatemia. Clinical studies show that coadministration of vadadustat with calcium acetate reduces vadadustat exposure up to 55%, suggesting a significant drug-drug interaction—vadadustat should ideally be administered at least one hour before calcium acetate to minimize interaction effects. This combination is commonly used in CKD patients on dialysis for concurrent management of anemia and elevated phosphate levels[1][3][4][5].

Other names

vadadustat + calcium acetate